### **ONLINE DATA SUPPLEMENT**

**SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae**

Tomasicchio  $M^{1,2}$ , Jaumdally  $S^{1,2}$ , Pooran A<sup>1,2</sup>, Esmail A<sup>1,2</sup>, Wilson L<sup>1,2</sup>, Kotze A<sup>1,2</sup>, Semple L<sup>1,2</sup>, Meier  $S^{1,2}$ , Pillay K<sup>5</sup>, Roberts R<sup>5</sup>, Kriel R<sup>5</sup>, Meldau R<sup>1,2</sup>, Oelofse S<sup>1,2</sup>, Mandviwala C<sup>1,2</sup>, Burns J<sup>1,2</sup>, Londt R<sup>1,2</sup>, Davids M<sup>1,2</sup>, van der Merwe<sup>1,2</sup> C, Roomaney A<sup>1,2</sup>, Kühn L<sup>1,2</sup>, Perumal T<sup>1,2</sup>, Scott A.J<sup>1,2</sup>, Hale M.J<sup>6</sup>, Baillie V<sup>7</sup>, Mahtab S<sup>7</sup>, Williamson C<sup>8</sup>, Joseph R<sup>8</sup>, Sigal A<sup>9</sup>, Joubert I<sup>10</sup>, Piercy J<sup>10</sup>, Thomson D<sup>10</sup>, Fredericks  $DL^{10}$ , Miller MGA<sup>10</sup>, Nunes M<sup>7</sup>, Madhi S.A<sup>7</sup>, Dheda K<sup>1,2,3,4</sup>.

<sup>1</sup> Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.

<sup>2</sup> South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

<sup>3</sup> Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

<sup>4</sup>Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.

<sup>5</sup> Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town, South Africa

<sup>6</sup> Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand.

<sup>7</sup> South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

<sup>8</sup> Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

<sup>9</sup> Africa Health Research Institute, Durban, South Africa.

<sup>10</sup> Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University of Cape Town, South Africa

Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South Africa. E-mail: keertan.dheda@uct.ac.za

#### **Supplementary methods.**

#### **Sample size.**

Samples sizes were calculated based on our primary endpoint measure i.e. the proportion of nasopharyngeal versus organ biopsy samples that were viral culturepositive. Based on the literature, viral replication can be demonstrated by culture approximately up to about 14 days post symptom onset. At  $\sim$ 14 days post symptom-onset, assuming a nasopharyngeal viral culture positivity rate of 5% or less and lung biopsy positivity rate of ~40%, a case to control ratio of 2:1, ~40 lung biopsy samples and ~20 controls, would allow us to detect a significant difference in groups at an alpha of 0.05 and with 80% power (OpenEpi, Version 3, opensource calculator). Thus, we were powered to detect a ~35% difference between the groups.



**Figure S1.** *In vitro* **culture of SARS-CoV-2.** (**A**) Light microscope images showing SARS-CoV-2 viral-induced cytopathic effects (red arrow). (**B**) Confocal microscopy showing SARS-CoV-2 (red) infecting the cell line. DAPI (blue) was used as the nuclear stain. (**C**) The limit of detection (LOD) for the PCR assay to detect replicating competent SARS-CoV-2. SARS-CoV-2 viral stock was diluted in 10-fold dilutions from  $1 \times 10^5$  to 1 copy/ml and co-cultured with confluent H1299 ACE2 cells in a 24-well plate for 9 days. Aliquots were analysed by PCR for viral load on days 1, 3, 6 and 9. The relative viral load (copies/ml) are shown. The dotted line represents the LOD for viral load  $(1\times10^{1}$ copies/ml).

# **Supplementary results.**

**Table S1. Demographic and clinical characteristics of the decedents.** 







p-values are for comparison between lung culture-positive and negative.

BMI status was only recorded for the Delta group.

\*Co-morbidities were only recorded for the Delta group. No patients had asthma, current TB, other chronic lung disease, cardiovascular disease, CVA/stroke, malnutrition, organ failure/disease, anaemia or epilepsy.

Vaccination status was only recorded for the Delta group.

Patients with dyslipidemia/varicose veins, ex-smoker, previous lateral medullary syndrome, previous heavy alcohol use, ischemic heart disease or trisomy.

Ct value at day of MITS sampling missing for 9 patients.

Either the viral load was too low or the sample was not available.

 $\triangle$  Only recorded for the Delta group.

 $\overline{\mathbf{A}}$ 

Lung biopsy viral culture in the Beta and Delta cohort

Proportion of nasopharyngeal swabs that are culturepositive at diagnosis (~5 days from symptom onset), 12 and 19 days from symptom onset in ambulatory patients



B

**Figure S2.** *In vitro* **viral culture of lung biopsies from MV decedents (A) and nasopharyngeal swabs from ambulatory control (B). (A) Description of a new SARS-CoV-2 human biophenotype that has ongoing viral replication in lung for up to 27 days post symptom onset. (B) Ambulatory patients do not have active replication competent SARS-CoV-2 in their NPS on day 19 post-symptom onset.** The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The lung biopsy samples were removed and placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator and viral replication were monitored on days 1, 3, 6 and 9 by PCR. DSOTD=days symptom onset to death.

56% of nasopharyngeal swabs (URT) from ambulatory patients were culture-positive at diagnosis (~5 days from symptom onset; Figure S2B) and the proportion of nasopharyngeal swabs that remained culture-positive beyond 12 days post symptom onset was low, at 5.5% (p=0.001) compared to 38% (p=0.038) for the lung biopsies (LRT) from the MV decedents (Figure 2B and S2B).



**Figure S3. Previously ventilated decedents had active replicating virus in the upper respiratory tract for up to 27 days post symptom onset to death.** (A) The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The nasopharyngeal swabs in universal transport medium were initially filtered through a 0.22µm filter prior to inoculation. The inoculated cultures were grown in a humidified  $37^{\circ}$ C incubator with 5% CO<sub>2</sub> and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown. The dotted lines represent the median days from symptom onset to death for the lung culture-positive (13 days) and lung culture-negative (18 days) decedents. The days from symptom onset to death for the culture-negative (-ve; green) and culturepositive (+ve; red) groups are shown for the Beta (**B**) and Delta (**C**) cohorts. The median days from symptom onset to death for the culture-positive (7 days for the Beta cohort and 16.5 days for the Delta cohort) and culture-negative (10.5 days for the Beta cohort and 23.5 days for the Delta cohort) participants are shown.

Similarly, to the lung culture data, we show that overall, the nasopharyngeal swab culture-positive group had accelerated death (13 day from symptom onset to death) compared to the lung culture-negative group (18 days from symptom onset to death; Figure S3B; p=0.017).



**Figure S4. The culture-positive participants from the Delta cohort, but not the Beta cohort, had a higher frequency of secondary bacterial infection compared to the culture-negative participants.**



**Figure S5. Electron micrographs of key clinical features of lung abnormalities associated with acute COVID-19 disease.** 



**Figure S6. Flow cytometry data showing (A) the gating strategy and expression of IFN-, TNF-α, IL-2 and IL-β from CD4+ (B) and CD8+ (C) lung-derived T-cells from the Delta decedents.** 

#### **Table S2. Histopathological data of the combined study cohort.**





\*Histopathology was not performed on all the biopsy samples.

#### **Table S3. Electron microscopy data of the Delta cohort.**



\*EM was only performed on biopsy samples in the Delta cohort.



**Figure S7. Gene expression profile in the culture-negative and culture-positive groups cluster into distinct groups.** PCA plot (**A**) and heatmap (**B**) showing that distinct genes are differentially regulated in the culture-positive and culture-negative groups.

Table S4. Whole genome sequencing results of the viral variants from the study cohort. Only 6 culture-negative and 6 culturepositive samples were available for sequencing because either the viral load was too low (Ct>30) or the sample was not available. It was therefore impossible to perform comparative analysis between the 2 groups because of the small sample number. Data was analysed and sequences aligned using the Stanford University Coronavirus Antiviral and Resistance Database (available at: https://covdb.stanford.edu/)





#### **Table S5. Transcriptomic analysis showing genes upregulated in the culture-positive cohort relative to the culture-negative cohort.**



# **Table S6A. Pathways upregulated in the culture-positive cohort relative to the culture-negative cohort.**





## **Table S6B. Other pathways of interest upregulated in the culture-positive cohort relative to the culture-negative cohort.**





#### **Table S6C. Genes associated with regulatory pathways of are not uo- or downregulated in the culture-positive cohort relative to the culture-negative cohort.**



#### **Supplementary results pertaining to the transcriptomic analysis.**

We obtained lung biopsy samples within ~2hrs postmortem to preserve the transcriptional signature. This is well within the postmortem interval (PMI) reported to preserve RNA stability and integrity in the lung <sup>1-3</sup>. One study reported that RNA stability could be preserved after a PMI as long as  $41 \text{hrs}^{-1}$ . The lung-culture-positive group express higher levels of carbonic anhydrase 12 (CA12) than the lung culture-negative group (Figure 5, S8 and Table S5). This protein induces a phenotype similar to high-altitude pulmonary oedema with a decreased ratio of arterial oxygen, partial pressure to fractional inspired oxygen, and a reduction of the carbon dioxide levels. This was associated increased tachypnoea and fibrinogen levels/fibrin formation and the presence of hypoxia leading to ARDS.

Another gene that was highly overexpressed in the culture-positive cohort was CD177, a glycosylphosphatidylinositol (GPI)-anchored protein expressed by neutrophils. CD177 plays a key role in neutrophil activation, transmigration and adhesion to the endothelium and are associated with the severity of Covid-19 disease<sup>4</sup> (Figure 5, S8 and Table S5). Fu et al <sup>5</sup> reported that neutrophil chemotaxis, infiltration of endothelial cells, and extravasation into alveolar spaces have been described in lung autopsies from deceased patients with COVID-19<sup>6</sup>. CD177 was recently identified by proteomics in bronchoalveolar lavage of COVID-19 patients <sup>6</sup> which supports our data of an upregulation of CD177 in our decedents. Our histopathological data support these findings where we show that the lung culture-positive group have higher infiltration of neutrophils into the alveoli than the ling-culture negative group.

Syndecan binding protein 2 was significantly upregulated in the culture-positive versus the culture-negative group (Figure 5, S8 and Table S5). The protein is a family member of the syndecans (SDC) which are transmembrane proteoglycans that facilitate the cellular entry of SARS-CoV-2<sup>7</sup>. Endothelial cells express SDC2 and during virus internalization, syndecans colocalize with ACE2, suggesting a jointly shared internalization pathway. Hudak et al <sup>7</sup> reported that entry via SDCs enabled efficient gene transduction with SARS-CoV-2 pseudovirus which implied that SDC-mediated internalisation pathway maintained the viral particles biological activity. Viruses that target SDCs in the lung may therefore interfere with SDC-dependent signalling as inhibitors to both ACE2 and syndecan reduced the cellular entry of SARS-CoV-2, thus supporting the complex nature of internalization.

The culture-positive group, compared to the culture-negative group, are associated with the enrichment of inflammatory, innate immune and enhanced SARS-CoV-2 entry pathways



Figure S8. The culture-positive group expressed higher levels of genes associated with inflammatory, innate immunity and enhanced SARS-CoV-2 cellular entry pathways compared to the **culture-negative cohort.** Volcano plots showing the pathways (**A**) and individual genes (**B and C**) upregulated in the culture-positive versus the culture-negative cohort. Gene expression profile of individual genes upregulated in the cytokine signalling (**D**), innate immune (**E**) and enhanced SARS-CoV-2 cellular entry (**F**) pathways in the culture-positive versus culture-negative cohort. Cyto = cytokine signalling, def. resp.virus = defence of respiratory virus, innate = innate immunology, inflame = inflammatory response, vir ent=viral entry. The red line represents FDR<0.05 and the black dotted

















**Figure S9. Key pathways up (red) and downregulated (green) in the culture-positive versus culture-negative decedents. Figures were constructed using the Kyoto Encyclopaedia of Genes and Genomes Database.**

#### **Supplemenraty references.**

- 1. De Paepe, M.E., et al. Postmortem RNA and protein stability in perinatal human lungs. *Diagn Mol Pathol* **11**, 170-176 (2002).
- 2. Fan, J., et al. Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. *Oncotarget* **7**, 66906-66921 (2016).
- 3. Floros, J., et al. The utility of postmortem lung for RNA studies; variability and correlation of the expression of surfactant proteins in human lung. *Exp Lung Res* **17**, 91-104 (1991).
- 4. Levy, Y.*, et al.* CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. *iScience* **24**, 102711 (2021).
- 5. Fu, J.*, et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb Res* **192**, 3-8 (2020).
- 6. Aschenbrenner, A.C.*, et al.* Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. *Genome Med* **13**, 7 (2021).
- 7. Hudak, A., Letoha, A., Szilak, L. & Letoha, T. Contribution of syndecans to the cellular entry of SARS-CoV-2. *Int J Mol Sci* **22**(2021).
- 8. Noske G D, d.S.S.E., de Godoy M O, Dolci I, Fernandes R S, Guido R V C, Sjö P, Oliva G. Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 Main Protease naturally occurring polymorphisms. *bioRxiv* (2022).